Here's Why You Should Add AngioDynamics Stock to Your Portfolio

Core Viewpoint - AngioDynamics, Inc. (ANGO) is positioned for growth due to the potential of its NanoKnife System, despite facing pricing pressure and macroeconomic challenges [1] Company Overview - AngioDynamics designs, manufactures, and sells a variety of medical, surgical, and diagnostic devices, focusing on minimally invasive procedures, with a market capitalization of $310.85 million [1] - The company projects a 7.6% earnings growth for fiscal 2026 and has surpassed earnings estimates in three of the last four quarters, with an average beat of 28.61% [1] Factors Favoring ANGO Stock - Broad Product Line: AngioDynamics specializes in minimally invasive medical devices, with a product portfolio that includes Microwave Ablation, Radiofrequency Ablation (RFA), and the NanoKnife system, which is in high demand for tumor treatments [3] - R&D Investments: The company is increasing its R&D expenses at a projected CAGR of 1.3% from fiscal 2024 to 2027 to enhance core technologies [3] - Regulatory Achievements: Recent regulatory successes, including CE Mark approval and FDA clearance for the AlphaVac F18 System, support commercial launches [3] Potential in NanoKnife System - The NanoKnife product has received FDA clearance for soft tissue surgical ablation and is designated as a Breakthrough Device, contributing to an 11.3% year-over-year increase in Med Tech segment sales [4] - Capital sales surged by 247.8%, indicating strong demand for disposables, with expectations for FDA clearance for prostate ablation by the end of 2024 [4] - Revenue projections indicate a 5.9% CAGR from fiscal 2024 to 2027, driven by a 10.3% CAGR in the Med Tech segment [4] Strong Geographic Expansion - In fiscal 2024, 85.6% of net sales came from the U.S., up from 83.5% in 2023, with international sales growing by 14% [5] - U.S. revenues increased by 4.3% in the fourth quarter of 2024, with anticipated steady growth at a CAGR of 2.2% in the U.S. and 0.5% internationally through 2027 [5] Estimate Trend - The earnings estimate for 2024 has improved, with the Zacks Consensus Estimate for loss narrowing from 47 cents to 41 cents per share [7] - The third-quarter 2024 revenue estimate is $68.49 million, reflecting a 13% decline from the previous year [7]